Project Grant R21CA303745
Award Date 6/1/26
Completion Date 5/31/28
Dollars Obligated $423K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
- Federal Project Grant Summary Northwestern University, through its Sponsored Research Division, received a $1,453,656 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) effective September 1, 2025, with a completion date of August 31, 2030. The grant funds research investigating the role of adverse social-biological interactions in acute myeloid leukemia (AML) disparities. The project leverages the multi-institutional Chicago AML...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $586,364 Project Grant to the University of California, Irvine on April 7, 2026, under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on Type 1 Innate Lymphoid Cells (ILC1s) and their potential therapeutic applications against acute myeloid leukemia (AML). The research will be conducted through March 31, 2031, and focuses on elucidating the mechanisms by which ILC1s target and...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $954,436 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) on September 23, 2025, with a completion date of July 31, 2030. The award funds fundamental cancer research investigating the mechanisms by which chronic myeloid leukemia (CML) leukemia stem cells persist during tyrosine kinase inhibitor (TKI) treatment through their interaction...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Missouri System $486,426 under the Cancer Biology Research program (CFDA 93.396) to conduct a five-year research project examining leukemic stem cell (LSC) interactions within the bone marrow microenvironment (niche) and developing niche-directed leukemia treatments. The research initiative, which commenced April 1, 2026 and concludes March 31, 2031, focuses on elucidating molecular crosstalk...
- Federal Project Grant Award Summary The University of Michigan received a $646,881 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026 through March 31, 2031. The award supports research focused on developing and validating ASH1L (Absent, Small or Homeotic 1-Like) histone methyltransferase inhibitors as a novel therapeutic approach for acute leukemia treatment. The research addresses a critical clinical...
- Federal Grant Award Summary Baylor College of Medicine received a $160,500 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective July 10, 2025, with completion targeted for June 30, 2027. The award funds the development and investigation of in vivo murine models to examine the role of caspase-2 in nucleophosmin-mutated acute myeloid leukemia (NPM1C+ AML). The research deliverables include the establishment of transgenic mouse...
- Federal Project Grant Award Summary The University of Illinois received a $565,909 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2031. This award funds fundamental research investigating microcalcifications (MCs) in breast cancer through the development and application of engineered mineralized hydrogels that replicate the tumor microenvironment (TME). The research addresses a critical gap...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $2,970,010 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 16, 2025, with completion targeted for August 31, 2029. The research initiative focuses on elucidating the tumorigenic mechanisms of somatic truncation mutations in KMT2D, which encodes the histone methyltransferase MLL4 (mixed-lineage leukemia 4), particularly as...
- Federal Grant Award Summary The National Cancer Institute awarded a $412,249 Project Grant to the University of Illinois under the Cancer Biology Research program (CFDA 93.396) to identify and validate novel innate immune checkpoint receptors that regulate phagocytosis and influence cancer immune evasion. The research addresses a critical gap in understanding how malignant cells exploit immune tolerance mechanisms, specifically investigating vascular cell adhesion molecule-1 (VCAM-1) and its...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...